The study achieved both primary independent endpoints: PFS with nivolumab-ipilimumab compared to chemotherapy, in patients whose tumors had a high tumor mutational burden (TMB) (≥10 mut/Mb), independently of PD-L1 expression; and OS, showing a superior benefit for nivolumab-ipilimumab compared to chemotherapy in advanced NSCLC patients whose tumors expressed PD-L1 ≥ 1% [33]. Here, CD274 is linked to neoplasm.